Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model
Previous
Previous
Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems
Next
Next